Balloon Angioplasty News and Research RSS Feed - Balloon Angioplasty News and Research

Balloon Angioplasty is a procedure to enlarge the opening in a blood vessel that has become narrowed or blocked by plaque (a buildup of fat and cholesterol on the inner wall of the blood vessel). A small balloon is filled with air inside the blood vessel to push the plaque against the blood vessel wall and increase the opening.
Abbott starts ABSORB Japan trial to evaluate Absorb BVS in patients with CAD

Abbott starts ABSORB Japan trial to evaluate Absorb BVS in patients with CAD

Abbott today announced that it has initiated the ABSORB Japan randomized controlled clinical trial to evaluate the Absorb Bioresorbable Vascular Scaffold in patients with coronary artery disease, the most common form of heart disease. [More]

Omega-3 fatty acids may reduce inflammation associated with cardiovascular procedures

MD-Procedures like angioplasty, stenting and bypass surgery may save lives, but they also cause excessive inflammation and scarring, which ultimately can lead to permanent disability and even death. [More]

Researchers examine new zinc-based bioabsorbable stents

In 2012, more than 3 million people had stents inserted in their coronary arteries. These tiny mesh tubes prop open blood vessels healing from procedures like a balloon angioplasty, which widens arteries blocked by clots or plaque deposits. After about six months, most damaged arteries are healed and stay open on their own. The stent, however, is there for a lifetime. [More]
Drug-eluting stents can keep clogged leg arteries open and prevent leg amputation

Drug-eluting stents can keep clogged leg arteries open and prevent leg amputation

Drug-eluting stents can keep clogged leg arteries open, preventing amputation of the leg, suggests research being presented at the Society of Interventional Radiology's 38th Annual Scientific Meeting in New Orleans. [More]
Interventional endovascular therapy is safe but does not improve MS outcomes: Study

Interventional endovascular therapy is safe but does not improve MS outcomes: Study

The first controlled clinical trial to test the safety and efficacy of interventional endovascular therapy on the symptoms and progression of multiple sclerosis has found that the intervention, sometimes called the "liberation treatment," which has attracted intense interest in the global MS community, does not improve patient outcomes. In a few cases, the treatment made symptoms worse. [More]

Major bleeding after PCI may increase in-hospital mortality

In a study that included 3.3 million percutaneous coronary intervention procedures, major bleeding after PCI was associated with significantly increased in-hospital mortality, with an estimated 12 percent of deaths after PCI related to bleeding complications, according to a study appearing in the March 13 issue of JAMA. [More]
EDTA chelation, high-dose vitamins/minerals may provide additional benefit for MI patients

EDTA chelation, high-dose vitamins/minerals may provide additional benefit for MI patients

Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. [More]
Clopidogrel pretreatment for PCI does not reduce risk of overall mortality

Clopidogrel pretreatment for PCI does not reduce risk of overall mortality

Among patients scheduled for a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), pretreatment with the antiplatelet agent clopidogrel was not associated with a lower risk of overall mortality but was associated with a significantly lower risk of major coronary events, according to a review and meta-analysis of previous studies published in the December 19 issue of JAMA. [More]
Riverside Methodist Hospital treats first PAD patient with Cook Medical's Zilver PTX device

Riverside Methodist Hospital treats first PAD patient with Cook Medical's Zilver PTX device

Just weeks after the Food and Drug Administration (FDA) approved Cook Medical's Zilver PTX Drug-Eluting Peripheral Stent, Riverside Methodist Hospital in Columbus, Ohio, has treated the first patient with the device as part of Cook's U.S. commercial launch. [More]

Enrollment complete in Tryton's Pivotal IDE Side Branch Stent trial to treat bifurcation lesions

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced the completion of enrollment in the TRYTON Pivotal IDE trial evaluating the Tryton Side Branch Stent. [More]
FDA approves Cook's Zilver PTX drug-eluting peripheral stent

FDA approves Cook's Zilver PTX drug-eluting peripheral stent

Angiotech Pharmaceuticals, Inc. announced that its partner Cook Medical, Inc. received approval on November 15, 2012 from the U.S. Food and Drug Administration to market and sell the proprietary Zilver PTX drug-eluting peripheral stent, adding the United States to the list of over 50 markets, including the European Union and Japan, where Zilver PTX is approved for sale. [More]

Cook receives FDA approval for Zilver PTX Drug-Eluting Peripheral Stent to treat PAD

The U.S. Food and Drug Administration approved the Zilver PTX Drug-Eluting Peripheral Stent (Zilver PTX Stent), the first drug-eluting stent indicated to re-open a particular artery in the thigh (femoropopliteal artery) when narrowed or blocked as a result of peripheral artery disease (PAD). [More]
Cilostazol reduces restenosis after angioplasty in critical limb ischemia

Cilostazol reduces restenosis after angioplasty in critical limb ischemia

The quinolinone derivative cilostazol may be associated with reduced restenosis, reocclusion, and clinically driven target lesion revascularization 3 months after infrapopliteal angioplasty, researchers say. [More]

St. Luke's cardiologist wins TCT 2012 Geoffrey O. Hartzler Master Clinical Operator Award

Barry D. Rutherford, MD, a world renowned interventional cardiologist, was presented the TCT 2012 Geoffrey O. Hartzler Master Clinical Operator Award in a ceremony held today during the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF). [More]

Drug-eluting balloon procedure can effectively treat peripheral artery disease

Use of balloon angioplasty and placement of stents to widen clogged arteries have become standard medical procedure. Further advancing this treatment, drug-eluting devices are now delivering medication directly to the site where it can be most effective. While this technique has met with success in coronary arteries, its use in peripheral arteries is still under study. [More]

Creighton University research to improve patient care and outcomes in CAD treatment

Since 1990, Creighton University School of Medicine professor and researcher Devendra K. Agrawal, Ph.D., has been awarded more than $20 million in research grants to study coronary artery heart disease. He is determined to eradicate the impact of this heart disease—the number one killer of men and women in the United States. [More]

Link between cardiac catheterizations and risk of stroke

When a patient undergoes a cardiac catheterization procedure such as a balloon angioplasty, there's a slight risk of a stroke or other neurological complication. [More]

Effective therapies to reduce perioperative morbidity and mortality remain elusive

Among intermediate- to high-risk patients undergoing coronary artery bypass graft surgery, administration of the agent acadesine to regulate adenosine (a naturally occurring chemical that dilates blood flow and can improve coronary blood flow and perfusion) did not reduce all-cause death, nonfatal stroke, or need for mechanical support for ventricular dysfunction, for approximately a month after surgery, according to a study in the July 11 issue of JAMA. [More]

Registry proves invaluable for fibromuscular dysplasia patients

A patient registry is proving invaluable in cataloging the clinical features, symptoms, severity, and outcomes of fibromuscular dysplasia (FMD), a non-inflammatory vascular disease that can cause narrowing of arteries in the carotid (neck) and renal (kidney) arteries, which can result in headache, strokes, and aneurysms. [More]

Patient registry yields new data that is crucial for early diagnosis and treatment of FMD

A patient registry is proving invaluable in cataloging the clinical features, symptoms, severity, and outcomes of fibromuscular dysplasia (FMD), a non-inflammatory vascular disease that can cause narrowing of arteries in the carotid (neck) and renal (kidney) arteries, which can result in headache, strokes, and aneurysms. [More]